Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer - results of a matched-pair analysis.
Standard
Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer - results of a matched-pair analysis. / Rades, Dirk; Schroeder, Ursula; Bajrovic, Amira; Schild, Steven E.
In: EUR J CANCER, Vol. 47, No. 18, 18, 2011, p. 2729-2734.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer - results of a matched-pair analysis.
AU - Rades, Dirk
AU - Schroeder, Ursula
AU - Bajrovic, Amira
AU - Schild, Steven E
PY - 2011
Y1 - 2011
N2 - The standard treatment for non-metastatic T3/T4 larynx and hypopharynx cancer varies. This study compared definitive radiochemotherapy to surgery followed by radio(chemo)therapy. Forty-four patients treated with radiochemotherapy were matched to 88 patients receiving surgery plus radio(chemo)therapy. Groups were matched 1:2 for eight factors including age, gender, performance status, tumour site, histologic grade, T-/N-category and AJCC stage. Groups were compared for loco-regional control, metastases-free survival, overall survival and toxicity. Two-year loco-regional control rates were 75% after surgery plus radio(chemotherapy) and 66% after radiochemotherapy (p=0.39). Metastases-free survival rates were 76% and 77%, respectively (p=0.76). Overall survival rates were 67% and 63%, respectively (p=0.95). During follow up, 60% and 9% of the patients, respectively, received a total laryngectomy (p=0.004). Grade ?3 oral mucositis and haematologic toxicity rates were higher with radiochemotherapy. Other toxicities were similar. Outcomes of radiochemotherapy appeared similar to those of surgery plus radio(chemo)therapy. The larynx preservation rate was higher after radiochemotherapy.
AB - The standard treatment for non-metastatic T3/T4 larynx and hypopharynx cancer varies. This study compared definitive radiochemotherapy to surgery followed by radio(chemo)therapy. Forty-four patients treated with radiochemotherapy were matched to 88 patients receiving surgery plus radio(chemo)therapy. Groups were matched 1:2 for eight factors including age, gender, performance status, tumour site, histologic grade, T-/N-category and AJCC stage. Groups were compared for loco-regional control, metastases-free survival, overall survival and toxicity. Two-year loco-regional control rates were 75% after surgery plus radio(chemotherapy) and 66% after radiochemotherapy (p=0.39). Metastases-free survival rates were 76% and 77%, respectively (p=0.76). Overall survival rates were 67% and 63%, respectively (p=0.95). During follow up, 60% and 9% of the patients, respectively, received a total laryngectomy (p=0.004). Grade ?3 oral mucositis and haematologic toxicity rates were higher with radiochemotherapy. Other toxicities were similar. Outcomes of radiochemotherapy appeared similar to those of surgery plus radio(chemo)therapy. The larynx preservation rate was higher after radiochemotherapy.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Combined Modality Therapy
KW - Neoplasm Staging
KW - Matched-Pair Analysis
KW - Chemoradiotherapy/adverse effects
KW - Hypopharyngeal Neoplasms/mortality/pathology/therapy
KW - Laryngeal Neoplasms/mortality/pathology/therapy
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Combined Modality Therapy
KW - Neoplasm Staging
KW - Matched-Pair Analysis
KW - Chemoradiotherapy/adverse effects
KW - Hypopharyngeal Neoplasms/mortality/pathology/therapy
KW - Laryngeal Neoplasms/mortality/pathology/therapy
M3 - SCORING: Journal article
VL - 47
SP - 2729
EP - 2734
JO - EUR J CANCER
JF - EUR J CANCER
SN - 0959-8049
IS - 18
M1 - 18
ER -
